Novel Insights into Bexarotene's Role in Preventing Cholestasis: Mechanisms and Implications

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2025 Feb 26

PMID 40009169

Authors

Thamer Abdulla Mohammed

Munaf H Zalzala

Affiliations

Soon will be listed here.

Abstract

Cholestasis is defined as an impairment in the flow of bile, resulting in the accumulation of its components. Despite ursodeoxycholic acid (UDCA) being the only FDA-approved drug for cholestasis, it has little value in treating or preventing cholestasis; hence, new medications are required to treat these illnesses. The farnesoid X receptor (FXR) maintains bile acid (BA) homeostasis. It exists as heterodimers with retinoid X receptor (RXR) and responds to ligands that bind to any one of the partners and are activated synergistically in the presence of both. The hepatoprotective effect of bexarotene (Bex) against cholestasis liver injury induced by α-naphthyl isothiocyanate (ANIT) was evaluated in male Wistar albino rats. Our study demonstrates that compared to the ANIT group, Bex improves liver function tests, liver histology, and considerably reduces inflammatory mediators. Additionally, antioxidant levels increased significantly. Besides that, Bex upregulates the gene expression of FXR, bile salt export pump, hepatocyte nuclear factor 1α, and small heterodimer partner. Moreover, it enhances antioxidative nuclear factor erythroid 2-related factor gene expression and the expression of the NAD(P)H quinone oxidoreductase 1, and heme-oxygenase 1 protein targets in the rats' livers, reinforcing its hepatoprotective potential. Furthermore, Bex increases protein expressions of FXR, The bile salt export pump, and sirtuin 1 levels in the rats' livers. This study demonstrates that Bex protects against ANIT-induced cholestasis. This protective strategy involves controlling BA metabolism, inhibiting inflammatory mediators, and reducing oxidative stress.

References

Barone M, Maiorano E, Ladisa R, Cuomo R, Pece A, Berloco P . Influence of ursodeoxycholate-enriched diet on liver tumor growth in HBV transgenic mice. Hepatology. 2003; 37(4):880-6. DOI: 10.1053/jhep.2003.50175. View

Begum S . Hepatic Nuclear Factor 1 Alpha (HNF-1α) In Human Physiology and Molecular Medicine. Curr Mol Pharmacol. 2019; 13(1):50-56. DOI: 10.2174/1874467212666190930144349. View

Blumberg B, Evans R . Orphan nuclear receptors--new ligands and new possibilities. Genes Dev. 1998; 12(20):3149-55. DOI: 10.1101/gad.12.20.3149. View

Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C . Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem. 2001; 276(42):38685-9. DOI: 10.1074/jbc.M105127200. View

Boehm M, Zhang L, Badea B, White S, Mais D, Berger E . Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem. 1994; 37(18):2930-41. DOI: 10.1021/jm00044a014. View

Cao P, Gan J, Wu S, Hu Y, Xia B, Li X . Molecular mechanisms of hepatoprotective effect of tectorigenin against ANIT-induced cholestatic liver injury: Role of FXR and Nrf2 pathways. Food Chem Toxicol. 2023; 178:113914. DOI: 10.1016/j.fct.2023.113914. View

Claudel T, Staels B, Kuipers F . The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol. 2005; 25(10):2020-30. DOI: 10.1161/01.ATV.0000178994.21828.a7. View

Contreras-Omana R, Velarde-Ruiz Velasco J, Castro-Narro G, Trujillo-Benavides O, Zamarripa-Dorsey F, Reyes-Dorantes A . Approach to the patient with cholestasis and jaundice syndrome. Joint AMH, AMG, and AMEG scientific position statement. Rev Gastroenterol Mex (Engl Ed). 2021; 87(1):80-88. DOI: 10.1016/j.rgmxen.2021.04.003. View

Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon R, Poupon R . The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005; 128(2):297-303. DOI: 10.1053/j.gastro.2004.11.009. View

10.

Cui S, Hu H, Chen A, Cui M, Pan X, Zhang P . SIRT1 activation synergizes with FXR agonism in hepatoprotection governing nucleocytoplasmic shuttling and degradation of FXR. Acta Pharm Sin B. 2023; 13(2):559-576. PMC: 9978964. DOI: 10.1016/j.apsb.2022.08.019. View

11.

Dietrich C, Ottenhoff R, de Waart D, Oude Elferink R . Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology. 2001; 167(1):73-81. DOI: 10.1016/s0300-483x(01)00459-0. View

12.

Farol L, Hymes K . Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004; 4(2):180-8. DOI: 10.1586/14737140.4.2.180. View

13.

Fiorucci S, Zampella A, Distrutti E . Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders. Curr Top Med Chem. 2012; 12(6):605-24. DOI: 10.2174/156802612799436678. View

14.

Goldfarb S, Singer E, Popper H . Experimental cholangitis due to alpha-naphthyl-isothiocyanate (ANIT). Am J Pathol. 1962; 40:685-98. PMC: 1949524. View

15.

He L, Guo C, Peng C, Li Y . Advances of natural activators for Nrf2 signaling pathway on cholestatic liver injury protection: a review. Eur J Pharmacol. 2021; 910:174447. DOI: 10.1016/j.ejphar.2021.174447. View

16.

Horn T, Torres K, Naylor J, Cwik M, Detrisac C, Kapetanovic I . Subchronic toxicity and toxicogenomic evaluation of tamoxifen citrate + bexarotene in female rats. Toxicol Sci. 2007; 99(2):612-27. DOI: 10.1093/toxsci/kfm181. View

17.

Jin H, Liu X, Feng X, Zhu W, Feng S, Cao L . Quercetin 7-rhamnoside protects against alpha-naphthylisothiocyanate (ANIT)-induced in cholestatic hepatitis rats by improving biliary excretion and inhibiting inflammatory responses. Front Pharmacol. 2023; 13:1116257. PMC: 9868710. DOI: 10.3389/fphar.2022.1116257. View

18.

Jung D, Kullak-Ublick G . Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology. 2003; 37(3):622-31. DOI: 10.1053/jhep.2003.50100. View

19.

Kim I, Ahn S, Inagaki T, Choi M, Ito S, Guo G . Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res. 2007; 48(12):2664-72. DOI: 10.1194/jlr.M700330-JLR200. View

20.

Kong B, Wang L, Chiang J, Zhang Y, Klaassen C, Guo G . Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology. 2012; 56(3):1034-43. PMC: 3390456. DOI: 10.1002/hep.25740. View